London, October 22, 2020 – Fitch Ratings has today announced that it has assigned Hikma Pharmaceuticals Plc (Hikma, Company) a ‘BBB-’ first-time Long-Term Issuer Default Rating (outlook: Stable). Hikma’s existing rating of BBB- (outlook: Stable) from S&P remains unchanged, and accordingly the Company has achieved investment grade status from two rating agencies.
22 October 2020
Corporate, Press Release
Khalid Nabilsi, CFO of Hikma said: “I am pleased to announce that Hikma has achieved investment grade status with two ratings agencies. Fitch’s announcement today confirms Hikma’s solid market position as well as our track record of profitability and cash generation.”